Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-102
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HB-102 is an investigational non-replicating arenavirus-based vaccine candidate developed by Hookipa Pharma in collaboration with Gilead Sciences for the treatment of chronic Hepatitis B Virus (HBV) infection. Utilizing Hookipa's proprietary Vaxwave® platform, HB-102 is based on a lymphocytic choriomeningitis virus (LCMV) vector engineered to express HBV-specific antigens, including core and surface proteins. The vaccine is designed to induce a robust T-cell response to target and eliminate HBV-infected cells, aiming for a functional cure. While HB-102 served as the initial lead in the HBV program, the collaboration has since advanced a replicating arenavirus candidate, HB-500 (TheraT® platform), into clinical trials.
- Other names
- HBV vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on HB-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-102.